Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
et al., Research Square, doi:10.21203/rs.3.rs-148845/v1 (Preprint) (meta analysis)
, Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection, Research Square, doi:10.21203/rs.3.rs-148845/v1 (Preprint) (meta analysis)
Meta analysis of 18 ivermectin RCTs with 2,282 patients showing faster viral clearance (dose and duration dependent), improved clinical recovery, and lower hospitalization and mortality. In six RCTs of moderate or severe infection, there was a 75% reduction in mortality, RR 0.25 [0.12-0.52], p = 0.0002.A documentary about the external influences changing the conclusions of this study, and the resulting negative impacts, can be found at [drtesslawrie.substack.com].A sponsor reportedly required the conclusion of this paper to be changed against the wishes of the authors (to suggest that more trials should be done as opposed to the existing evidence being sufficient) [francesoir.fr, reddit.com, youtube.com]. Reportedly, Unitaid had influence over the conclusions [trialsitenews.com, worldcouncilforhealth.org]. See also [roundingtheearth.substack.com].Note that one of the 18 studies in this analysis has since been withdrawn (Elgazzar).Currently there are 95 ivermectin studies and meta analysis shows:
| Outcome | Improvement |
|---|---|
| Mortality | 51% lower [37‑62%] |
| Ventilation | 29% lower [13‑42%] |
| ICU admission | 41% lower [16‑58%] |
| Hospitalization | 34% lower [20‑45%] |
| Cases | 78% fewer [67‑85%] |
|
risk of death, 75.0% lower, RR 0.25, p < 0.001.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Hill et al., 19 Jan 2021, preprint, 40 authors.
Abstract: Meta-analysis of randomized trials of ivermectin to
treat SARS-CoV-2 infection
Andrew Hill ( andrewhillmv@gmail.com )
University of Liverpool
Ahmed Abdulamir
College of Medicine, Alnahrain University, Baghdad, Iraq
Sabeena Ahmed
International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh,
Asma Asghar
Department of Medicine, Combined Military Hospital, Lahore, Pakistan
Olufemi Emmanuel Babalola
Bingham University / Lagos University, Nigeria
Rabia Basri
Fatima Memorial Hospital, Lahore, Pakistan
Carlos Chaccour
Barcelona Institute for Global Health, Clinica Universidad de Navarra, Spain
Aijaz Zeeshan Khan Chachar
Fatima Memorial Hospital, Lahore, Pakistan
Abu Tauib Mohammed Chowdhury
Xi'an Jiaotong University Medical College First A liated Hospital, Shaannxi, China
Ahmed Elgazzar
Faculty of Medicine, Benha University, Benha, Egypt
Leah Ellis
Faculty of Medicine, Imperial College, London, UK
Jonathan Falconer
Department of Infectious Diseases, Chelsea and Westminster Hospital, London, UK
Anna Garratt
Department of Infectious Diseases, University Hospital of Wales, Cardiff and Vale University Health
Board, UK
Basma Hany
Faculty of Medicine, Benha University, Benha, Egypt
Hashim A Hashim
Alkarkh Hospital, Alate ya, Baghdad, Iraq
Wasim Ul Haque
Department of Nephrology, BIRDEM General Hospital, Dhaka, Bangladesh
Arshad Hayat
Department of Medicine, Combined Military Hospital, Lahore, Pakistan
Shuixiang He
Xi'an Jiaotong University Medical College First A liated Hospital, Shaanxi, China
Ramin Jamshidian
Jundishapur University School of Medical Sciences, Ahvaz, Iran
Wasif Ali Khan
International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh
Ravi Kirti
Department of General Medicine, All India Institute of Medical Sciences, Patna, India
Alejandro Krolewiecki
Instituto de Investigatiaciones de Enferedades Tropicales, Sede Regional Oran, Universidad National de
Salta, Argentina
Carlos Lanusse
Laboratorio de Farmacologia, Universidad de Buenos Aires, Argentina
Jacob Levi
Department of Intensive Care, University College London, UK
Reaz Mahmud
Department of Neurology, Dhaka Medical College, Dhaka, Bangladesh
Sermand Ahmed Mangat
Department of Medicine, Combined Military Hospital, Lahore, Pakistan
Kaitlyn McCann
Faculty of Medicine, Imperial College, London, UK
Anant Mohan
Department of Pulmonary Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New
Delhi, India
Mortezza Shakshi Niaee
Qazvin Science and Technology Park, Qazvin, Iran
Nurullah Okumus
Department of Neonatology, Afyonkarahisar Health Sciences University, Afkonkarahisar, Turkey
Victoria Pilkington
Oxford University, Clinical Academic Graduate School, University of Oxford, UK
Chinmay Saha Podder
Debidwar Upazila Health Complex, Debidwar, Comilla, Bangladesh
Ambar Qavi
Faculty of Medicine, Imperial College, London, UK
Houssam Raad
Biotherapies e Maladies Genetiques et Cancer, Universite Bordeaux, Segalen, France
Mohammaed Sadegh Rezai
Pediatric Infectious Diseases Research Centre, Communicable Diseases Institute, Mazandaran
University of Medical Sciences, Sari, India
Surapaneni Sasank
Gandhi University, Andhra Pradesh, India
Veerapaneni Spoorthi
Apollo Medical College, Hyderabad, India
Tejas Suri
Qazvin Science and Technology Park, Qazvin, Iran
Junzheng Wang
Faculty of Medicine, Imperial College, London, UK
Hannah Wentzel
Faculty of Medicine, Imperial College, London
Systematic Review
Keywords: ivermectin, COVID-19, SARS-CoV-2
Posted Date:..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.